Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
W

ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) - Tumor Treating Fields Concomitant With CRT and Maintenance TTFields Therapy/Temozolomide in Newly Diagnosed Glioblastoma"

By Insights from 2023 ASCO® Annual Meeting FEATURING Wenyin Shi
By Insights from 2023 ASCO® Annual Meeting FEATURING Wenyin Shi
109 views
June 8, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

17:48
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh
CNS
21:24

Breaking Bad Barriers: Brain-Penetrant Small Molecule Inhibitors

Insights from 2023 ASCO® Annual Meeting

A. Shergill

105 views
06:05

ASCO® 2023 Insights: "Phase 3 INDIGO Study Updates - Vorasidenib vs.…

Insights from 2023 ASCO® Annual Meeting

M. Preusser

316 views
04:02

ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) - Tumor Treating…

Insights from 2023 ASCO® Annual Meeting

W. Shi

109 views